Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.68 | N/A | -13.53% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.68 | N/A | -13.53% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions impacting performance. They remain committed to their long-term goals.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term strategies despite short-term hurdles.
Ligand Pharmaceuticals reported lower-than-expected earnings per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance left investors uncertain about the company's future performance. The 11.38% decline in stock price reflects market disappointment and concerns over ongoing challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ARCH CAPITAL GROUP L
Jul 29, 2019